Published in Pharmacol Res on June 23, 2007
Regulation of the fructose transporter GLUT5 in health and disease. Am J Physiol Endocrinol Metab (2008) 1.92
The divergence, actions, roles, and relatives of sodium-coupled bicarbonate transporters. Physiol Rev (2013) 1.50
Apelin targets gut contraction to control glucose metabolism via the brain. Gut (2015) 1.41
Significance and regional dependency of peptide transporter (PEPT) 1 in the intestinal permeability of glycylsarcosine: in situ single-pass perfusion studies in wild-type and Pept1 knockout mice. Drug Metab Dispos (2010) 1.14
Effect of dose escalation on the in vivo oral absorption and disposition of glycylsarcosine in wild-type and Pept1 knockout mice. Drug Metab Dispos (2011) 0.90
Angiotensin II-regulated microRNA 483-3p directly targets multiple components of the renin-angiotensin system. J Mol Cell Cardiol (2014) 0.86
Peptide transporter 1 is responsible for intestinal uptake of the dipeptide glycylsarcosine: studies in everted jejunal rings from wild-type and Pept1 null mice. J Pharm Sci (2010) 0.81
Species-dependent uptake of glycylsarcosine but not oseltamivir in Pichia pastoris expressing the rat, mouse, and human intestinal peptide transporter PEPT1. Drug Metab Dispos (2012) 0.81
Endogenous luminal surface adenosine signaling regulates duodenal bicarbonate secretion in rats. J Pharmacol Exp Ther (2010) 0.80
Role of the equilibrative and concentrative nucleoside transporters in the intestinal absorption of the nucleoside drug, ribavirin, in wild-type and Ent1(-/-) mice. Mol Pharm (2012) 0.77
Sodium glucose cotransporter SGLT1 as a therapeutic target in diabetes mellitus. Expert Opin Ther Targets (2016) 0.77
Expression of intestinal transporter genes in beagle dogs. Exp Ther Med (2012) 0.75
Microarray Determination of the Expression of Drug Transporters in Humans and Animal Species Used for the Investigation of Nasal Absorption. Mol Pharm (2015) 0.75
Di- and tripeptide transport in vertebrates: the contribution of teleost fish models. J Comp Physiol B (2016) 0.75
Reassessment of GLUT7 and GLUT9 as Putative Fructose and Glucose Transporters. J Membr Biol (2017) 0.75
Molecular properties of WHO essential drugs and provisional biopharmaceutical classification. Mol Pharm (2004) 2.63
A provisional biopharmaceutical classification of the top 200 oral drug products in the United States, Great Britain, Spain, and Japan. Mol Pharm (2006) 2.07
A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol Cancer Ther (2008) 2.07
Sulforaphane, a dietary component of broccoli/broccoli sprouts, inhibits breast cancer stem cells. Clin Cancer Res (2010) 1.96
A mechanistic approach to understanding the factors affecting drug absorption: a review of fundamentals. J Clin Pharmacol (2002) 1.85
St John's wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole. Clin Pharmacol Ther (2004) 1.79
Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm Res (2002) 1.74
Polymer degradation and in vitro release of a model protein from poly(D,L-lactide-co-glycolide) nano- and microparticles. J Control Release (2003) 1.72
Withaferin A targets heat shock protein 90 in pancreatic cancer cells. Biochem Pharmacol (2010) 1.69
A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment. J Med Chem (2011) 1.58
Structural studies of a bacterial condensin complex reveal ATP-dependent disruption of intersubunit interactions. Cell (2009) 1.58
The use of BDDCS in classifying the permeability of marketed drugs. Pharm Res (2008) 1.57
Characterization of celastrol to inhibit hsp90 and cdc37 interaction. J Biol Chem (2009) 1.45
Lessons learned from marketed and investigational prodrugs. J Med Chem (2004) 1.43
Summary workshop report: biopharmaceutics classification system--implementation challenges and extension opportunities. J Pharm Sci (2004) 1.43
A novel small-molecule inhibitor of mcl-1 blocks pancreatic cancer growth in vitro and in vivo. Mol Cancer Ther (2013) 1.42
Temporal expression of cytokines and their receptors mRNAs in a neuropathic pain model. Neuroreport (2004) 1.40
Near-infrared fluorescence labeled anti-TAG-72 monoclonal antibodies for tumor imaging in colorectal cancer xenograft mice. Mol Pharm (2009) 1.38
Comparison of human duodenum and Caco-2 gene expression profiles for 12,000 gene sequences tags and correlation with permeability of 26 drugs. Pharm Res (2002) 1.37
Prediction of solubility and permeability class membership: provisional BCS classification of the world's top oral drugs. AAPS J (2009) 1.37
Spinal NF-kB activation induces COX-2 upregulation and contributes to inflammatory pain hypersensitivity. Eur J Neurosci (2004) 1.36
Glucose uptake inhibitor sensitizes cancer cells to daunorubicin and overcomes drug resistance in hypoxia. Cancer Chemother Pharmacol (2006) 1.31
New developments in Hsp90 inhibitors as anti-cancer therapeutics: mechanisms, clinical perspective and more potential. Drug Resist Updat (2009) 1.27
Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharm Res (2006) 1.26
Gene expression profiling of cancer stem cell in human lung adenocarcinoma A549 cells. Mol Cancer (2007) 1.22
Characterization of a stem cell population in lung cancer A549 cells. Biochem Biophys Res Commun (2008) 1.22
Amino acid ester prodrugs of the anticancer agent gemcitabine: synthesis, bioconversion, metabolic bioevasion, and hPEPT1-mediated transport. Mol Pharm (2005) 1.21
Identification of a human valacyclovirase: biphenyl hydrolase-like protein as valacyclovir hydrolase. J Biol Chem (2003) 1.19
Synergistic antipancreatic tumor effect by simultaneously targeting hypoxic cancer cells with HSP90 inhibitor and glycolysis inhibitor. Clin Cancer Res (2008) 1.19
Physiological parameters for oral delivery and in vitro testing. Mol Pharm (2010) 1.18
A potent small-molecule inhibitor of the MDM2-p53 interaction (MI-888) achieved complete and durable tumor regression in mice. J Med Chem (2013) 1.17
An asymmetric SMC-kleisin bridge in prokaryotic condensin. Nat Struct Mol Biol (2013) 1.17
Activation of p38 MAP kinase in the rat dorsal root ganglia and spinal cord following peripheral inflammation and nerve injury. Neuroreport (2002) 1.17
The suitability of an in situ perfusion model for permeability determinations: utility for BCS class I biowaiver requests. Mol Pharm (2006) 1.16
A survey of ectoparasite infestations in stray dogs of Gwang-ju City, Republic of Korea. Korean J Parasitol (2008) 1.14
Gintonin, newly identified compounds from ginseng, is novel lysophosphatidic acids-protein complexes and activates G protein-coupled lysophosphatidic acid receptors with high affinity. Mol Cells (2012) 1.13
Fabrication of indocyanine green encapsulated biodegradable microbubbles for structural and functional imaging of cancer. J Biomed Opt (2009) 1.12
The BCS, BDDCS, and regulatory guidances. Pharm Res (2011) 1.11
Implications of cancer stem cell theory for cancer chemoprevention by natural dietary compounds. J Nutr Biochem (2011) 1.10
Pharmacokinetics of an immediate release, a controlled release and a two pulse dosage form in dogs. Eur J Pharm Biopharm (2005) 1.10
The role of TRPV6 in breast carcinogenesis. Mol Cancer Ther (2008) 1.10
Histone deacetylase inhibitors through click chemistry. J Med Chem (2008) 1.10
Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol (2009) 1.08
A novel nucleoside prodrug-activating enzyme: substrate specificity of biphenyl hydrolase-like protein. Mol Pharm (2005) 1.04
Molecular basis of prodrug activation by human valacyclovirase, an alpha-amino acid ester hydrolase. J Biol Chem (2008) 1.04
Floxuridine amino acid ester prodrugs: enhancing Caco-2 permeability and resistance to glycosidic bond metabolism. Pharm Res (2005) 1.04
(-)-Epigallocatechin-3-gallate inhibits Hsp90 function by impairing Hsp90 association with cochaperones in pancreatic cancer cell line Mia Paca-2. Mol Pharm (2009) 1.03
Targeted delivery to PEPT1-overexpressing cells: acidic, basic, and secondary floxuridine amino acid ester prodrugs. Mol Cancer Ther (2005) 1.03
Summary workshop report: bioequivalence, biopharmaceutics classification system, and beyond. AAPS J (2008) 1.01
Synthesis and enzyme-specific activation of carbohydrate-geldanamycin conjugates with potent anticancer activity. J Med Chem (2005) 1.00
Synthesis and initial evaluation of YM-08, a blood-brain barrier permeable derivative of the heat shock protein 70 (Hsp70) inhibitor MKT-077, which reduces tau levels. ACS Chem Neurosci (2013) 1.00
Analogs of the Allosteric Heat Shock Protein 70 (Hsp70) Inhibitor, MKT-077, as Anti-Cancer Agents. ACS Med Chem Lett (2013) 1.00
Multiple efflux pumps are involved in the transepithelial transport of colchicine: combined effect of p-glycoprotein and multidrug resistance-associated protein 2 leads to decreased intestinal absorption throughout the entire small intestine. Drug Metab Dispos (2009) 1.00
Potent bivalent Smac mimetics: effect of the linker on binding to inhibitor of apoptosis proteins (IAPs) and anticancer activity. J Med Chem (2011) 1.00
Antitumor activity of Triolimus: a novel multidrug-loaded micelle containing Paclitaxel, Rapamycin, and 17-AAG. Mol Cancer Ther (2012) 1.00
Diastereomeric spirooxindoles as highly potent and efficacious MDM2 inhibitors. J Am Chem Soc (2013) 1.00
Amino acid ester prodrugs of floxuridine: synthesis and effects of structure, stereochemistry, and site of esterification on the rate of hydrolysis. Pharm Res (2003) 1.00
Gene expression in the human intestine and correlation with oral valacyclovir pharmacokinetic parameters. J Pharmacol Exp Ther (2003) 0.99
High-permeability criterion for BCS classification: segmental/pH dependent permeability considerations. Mol Pharm (2010) 0.99
Segmental dependent transport of low permeability compounds along the small intestine due to P-glycoprotein: the role of efflux transport in the oral absorption of BCS class III drugs. Mol Pharm (2009) 0.98
Population pharmacokinetics of humanized monoclonal antibody HuCC49deltaCH2 and murine antibody CC49 in colorectal cancer patients. J Clin Pharmacol (2007) 0.98
Applications of human pharmacokinetic prediction in first-in-human dose estimation. AAPS J (2012) 0.98
In vitro testing of drug absorption for drug 'developability' assessment: forming an interface between in vitro preclinical data and clinical outcome. Curr Opin Drug Discov Devel (2004) 0.97
Development of a new QuEChERS method based on dry ice for the determination of 168 pesticides in paprika using tandem mass spectrometry. J Chromatogr A (2011) 0.96
Enhancing the intestinal membrane permeability of zanamivir: a carrier mediated prodrug approach. Mol Pharm (2011) 0.96
Interleukin-6 induces microglial CX3CR1 expression in the spinal cord after peripheral nerve injury through the activation of p38 MAPK. Eur J Pain (2009) 0.96
The solubility-permeability interplay in using cyclodextrins as pharmaceutical solubilizers: mechanistic modeling and application to progesterone. J Pharm Sci (2010) 0.95
Expression of monocyte chemoattractant protein-1 in rat dorsal root ganglia and spinal cord in experimental models of neuropathic pain. Brain Res (2008) 0.95
Superparamagnetic iron oxide nanotheranostics for targeted cancer cell imaging and pH-dependent intracellular drug release. Mol Pharm (2010) 0.95
Blockade of interleukin-6 receptor suppresses the proliferation of H460 lung cancer stem cells. Int J Oncol (2012) 0.95
Feasibility of biowaiver extension to biopharmaceutics classification system class III drug products: cimetidine. Clin Pharmacokinet (2006) 0.95
Monocyte chemoattractant protein-1 immunoreactivity in sensory ganglia and hindpaw after adjuvant injection. Neuroreport (2008) 0.95
Biodegradable self-assembled nanoparticles of poly (D,L-lactide-co-glycolide)/hyaluronic acid block copolymers for target delivery of docetaxel to breast cancer. Biomaterials (2013) 0.94
In vivo cancer imaging by poly(ethylene glycol)-b-poly(ɛ-caprolactone) micelles containing a near-infrared probe. Nanomedicine (2011) 0.94
Surfactant-mediated dissolution: contributions of solubility enhancement and relatively low micelle diffusivity. J Pharm Sci (2004) 0.94
Tumor necrosis factor receptor 1 induces interleukin-6 upregulation through NF-kappaB in a rat neuropathic pain model. Eur J Pain (2008) 0.94
Grapefruit juice and its constituents augment colchicine intestinal absorption: potential hazardous interaction and the role of p-glycoprotein. Pharm Res (2008) 0.94
Enhanced cancer cell growth inhibition by dipeptide prodrugs of floxuridine: increased transporter affinity and metabolic stability. Mol Pharm (2008) 0.93